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1 Introduction 
1.1 Hematopoietic differentiation and acute myeloid leukemia (AML)  
A cellular evolution of the pluripotential haematopoietic stem cells 
(HSCs) that normally leads to mature functional blood cells constitutes 
what is termed as hematopoiesis. Hematopoiesis is a very elaborate, 
sophisticated and dynamic physiological process. The bone marrow of a 
normal man weighing 70 kg produces each day some 210 x 108 mature 
erythrocytes, 175 x 108 platelet, and 60 x 108 neutrophil granulocytes (Mary 
et al., 1980).  
 
 
Figure 1. Haematopoietic development from a stem cell and 
         role of transcription factors (Tenen, 2003) 
 
During a 70-year life of an individual, approximately 650 kg of erythrocytes 
and 1000 kg of white blood cells are produced by the hematopoitic system 
(Afenya, 1996). In the hematopoietic development model, mature myeloid 
cells develop from hematopoietic stem cells through progenitors that 
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include common myeloid progenitors (CMPs) and, subsequently, 
granulocyte/ macrophage progenitors (GMPs) (Tenen, 2003). Myeloid cells 
include the common precursor for monocytes and granulocytes, and their 
more mature progeny (Figure1). During the process of hematopoietic 
lineage development, various transcription factors have been found to be 
crucial from studies involving either targeted disruption or overexpression 
of these factors (Shivdasani and Orkin, 1996; Tenen, 2003). 
Acute myeloid leukemia (AML) is a disease that is characterized by a 
block in the normal process of myeloid differentiation thereby leading to the 
accumulation of immature cells termed blasts (Lowenberg et al., 1999; 
Tenen et al., 1997, Figure 2). The abnormal maturation in AML could result 
from disruption of the function of transcription factors, cytokine receptors 
and the cell cycle. In other words, leukemic transformation might involve 
abnormalities of the transcription factors that normally regulate myeloid 
development in a stepwise fashion. 
It has been postulated that the origins of AML can be found in 
pluripotent stem cells (McCulloch, 1983; McCulloch, 1984; McCulloch and 
Till, 1981). It is, therefore, suggestive that in the AML state, pluripotent 
stem cells in the bone marrow become malignant, proliferate, and give 
birth to leukemic blasts. These blasts have a growth advantage over their 
normal counterparts in part due to increased survival of leukemic blast 
cells (Ferrari et al., 1992). These leukemic blasts suppress and replace 
normal haematopoietic progenitors leading to haematopoietic insufficiency. 
The diagnosis of AML is made clinical: i) if at least 30% of nucleated cells 
in the bone marrow are myeloblasts or ii) in the case of bone marrow 
showing erythroid predominance, if at least 30% of nonerythroid cells are 
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myeloblasts, or iii) if the characteristic signs of hypergranular promyelocytic 
leukemia are present (Bennett et al., 1985). 
 
Figure 2. Differentiation block characterizes AML and its 
reversal constitutes differentiation therapy 
 
The French-American-British, or FAB, classification has been the 
standard system used to classify the acute leukemias. AML is divided into 
eight major FAB subtypes (M0- M7), which are defined by morphology and 
immunophenotype (Casasnovas et al., 1998; Harris et al., 1999). However, 
the choice of therapy often depends upon the specific cytogenetic 
abnormality found in the leukemc blasts rather than their morphology or 
degree of differentiation. More than half of the AML patients display 
detectable and usually single cytogenetic abnormalities (Olsson et al., 
1996). Balanced chromosomal translocations are the most specific genetic 
lesions in AML and may represent critical, early events in the genesis of 
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the leukemic clone. The most common translocations are listed (Table 1). 
Myeloid cell restricted transcription factors are prime targets for 
chromosomal translocations in AML, since disruption of these factors can 
give growth advantage due to lack of terminal development (Scandura et 
al., 2002). Disruption of some transcription factors such as SCL or AML1 
affects formation of the entire blood cell lineage while other transcription 
factors such as GATA1, PU.1 and C/EBPalpha usually affect only a single 
or small number of related lineages (Tenen, 2003).  
 
Table 1. Common translocations in AML (Lowenberg B, 1999) 
Translocation 
 
     Genes involved           Morphology 
t(8;21)(q22;q22) AML1/ETO M2 (90%), Mild narrow 
eosinophilia 
t(16;21)(q24;q22) 
t(3;21)(q26;q22) 
AML1/MTG16 
AML1/EV11 
Variable 
Variable 
Inv(16)(p13;q22) CFBβ/MYH11 M4Eo (almost 
exclusively), rarely M4, 
M5, M2 also with 
abnormal marrow 
eosinophilia 
t(16;16)(p13;q22) 
del(16)(q22) 
CFBβ/MYH11 
CFBβ? 
As for inv (16) 
M4, M2 (probably no) 
M4Eo with out 
CFBβ/MYH11 
t(15;17)(q22;q12) PML/RARα M3 (exclusively) 
t(11;17)(q23;q12) PMLF/RARα M3 (exclusively) 
t(5;17)(q35;q12) 
t(11;17)(q13;q12) 
t(17;17)(q11;q12) 
t(4;11)(q21;q23) 
NPM/ RARα 
NuMA/ RARα 
STAT5b/RARα 
MLL/AF4 
M3 (exclusively) 
M3 (exclusively) 
M3 (exclusively) 
Most commonly 
associated with infant 
ALL 
t(6;11)(q27;q23) MLL/AF6 M4 or M5 (& T-ALL) 
t(9;11)(q22;q23) MLL/AF9 M4 or M5 
t(11;19)(q23;p13;3) MLL/ENL Biphenotypic; Pre-B 
ALL; M4 or M5 
t(11;19)(q23;p13.1) MLL/ELL M4 or M5 
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t(11;19)(q23;p13.3) 
t(11;16)(q23;p13) 
MLL/EEN 
MLL/CBP 
M4 or M5 
M4 or M5, occasional 
dyserythropoiesis 
t(11;22)(q23;p13) MLL /p300  
t(7;11)(p15;p15) NUP98/HOXA9 M2 or M4 
t(2;11)(q31;p15) NUP98/HOXD13 Variable 
t(1;11)(q24;p15) NUP98/PMX1 M2 
inv(11)(p15;q22) 
t(6,9)(p23;q34) 
NUP98/DDX10 
DEK/CAN 
(NUP214) 
 
M2 or M4, bone marrow 
basophilia, 
myelodysplasia with 
ringed sideroblasts 
t(18;16)(p11;p13) MOZ/CBP FAB M4 or M5, bone 
marrow 
erythropagocytosis 
t(9;22)(q34;q11) 
t(3;3)(q21;q26) 
BCR/ABL 
EVI-1 (overexpression) 
M1 or M2 
Megakaryocytic 
dysplasia and often 
trilineage dysplasia  
inv(3)(q21;q26) EVI-1 (overexpression) Megakaryocytic 
dysplasia and often 
trilineage dysplasia 
t(16;21)(p11;q22) TLS/ERG Variable FAB; extensive 
bone marrow 
hemophagocytosis 
del(17p) P53 mutations Characteristic 
dysgranulopoiesis 
 
 
1.2 Induction of differentiation: Differentiation therapy in AML 
AML treatment is based on intensive chemotherapy administered as; 
a) induction treatment that aims to bring the patient into complete 
hematological remission, and b) treatment in remission that aims to 
eradicate residual disease and prevent AML relapse (Lowenberg et al., 
1999). Treatment in remission with intensive chemotherapy alone or in 
combination with stem cell transplantation is associated with a relatively 
high mortality (Bruserud et al., 2000; Lowenberg et al., 1999). The use of a 
less aggressive therapy is therefore, highly desirable. One potential 
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approach might be the induction of differentiation of leukemic blasts 
turning them into non-dividing end cells. 
In an experimental setting AML cells can be induced to differentiate 
with a variety of agents. In 1978, Sachs and co-workers demonstrated that 
mouse cells undergo differentiation in the presence of IL6 (Sachs, 1978). 
Later it was reported that the vitamin A metabolite, retinoic acid (RA), 
could induce differentiation in the betty-60 cell line (Breitman et al., 1980), 
with the effect mediated through the RAR (Collins et al., 1990). The 
application of differentiation therapy with ATRA is now regarded as choice 
for the treatment of AML-M3: APL (He et al., 1999; Lo et al., 1998; Kogan 
and Bishop, 1999). There are currently a large number of prototypes and 
second-generation agents that are capable of inducing differentiation in 
either myeloid or lymphoid cell lines (Hozumi, 1998; Tallman, 1996), many 
of which have been used in clinical situations, albeit in only few cases, 
often this is in combination with other factors (Table 2a & 2b). Going 
further ahead in differentiation induction, antibody-based therapy for acute 
leukemia has evolved as a possible means of decreasing both relapse 
rates and mortality (Ruffner and Matthews, 2000). Over the past 25 years, 
monoclonal antibodies have been evaluated as anti-leukemic therapy both 
in unmodified forms and as immunoconjugates labeled with either 
radioactive or cytotoxic moieties. For example, anti-GM-CSF antibody 
(Bouabdallah et al., 1998), humanized anti-CD33 antibody (HuM-195) 
(Caron et al., 1998) or 131I-labeled anti-CD33 (p67) (Sievers et al., 1999) 
and anti-CD45 antibody (Sievers, 2000). Most monoclonal antibody 
targeting approaches have been directed against normal hematopoietic 
cell surface antigens that are also expressed by leukemic blast cells 
(Sievers, 2000). 
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Table 2a: Differentiation inducers of AML (Hozumi, 1998)  
Direction of 
differentiation 
Soluble mediators used Detection of 
differentiation in native 
AML blasts 
Neutrophil granulocyte SCF or IL-3 
 
 
 
 
 
IL-3, G-CSF, or GM-CSF 
 
 
 
 
 
IFN- , TNF- , Vit-D3, or 
retinoic acid 
 
 
 
 
 
 
 
 
SCF 
Induction of CD15 
expression and 
promyelocyte-myelocyte 
morphology in CD34+ 
AML-M1/M2 blasts. 
 
Increased proportions of 
mature granulocytes for 
some patients, no 
correlation between 
differentiation induction 
and FAB class. 
 
Enhanceddifferentiation 
when G-CSF was 
combined with retinoic acid 
decreased colony 
formation in clonogenic 
assay; these effects were 
caused by single agents 
and/or by combinations of 
mediators. 
Differentiation into 
myelocyte- and 
metamyelocyte-like 
leukemic cells with 
disappearance of CD34 
and HLA-DR expression 
for a subset of patients. 
Eosinophil granulocyte IL-5 Induction of either pure or 
mixed leukemic 
eosinophilic colonies, no 
correlation with FAB 
classification. 
Basophilic granulocyte SCF 
 
 
 
 
 
IFN- , TNF- , 
  
Differentiation into cells 
with segmented nuclei and 
basophilic /metachromatic 
granules for a small 
minority of patients. 
 
Increased membrane 
expression of the 
monocyte marker CD14 in 
subsets of patients; effects 
were caused by single 
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agents or combinations of 
mediators. 
Monocyte Vit-D3, or retinoic acid  
TNF-  
 
 
 
 
 
IL-3, GM-CSF, G-CSF, or M-
CSF 
 
 
 
 
SCF 
Leukemia inhibitory factor 
Induction of monocytic 
morphology with increased 
phagocytic capacity and 
expression of CD11b and 
CD14. 
 
Induction of a macrophage-
like morphology and 
expression of CD13, CD14, 
and HLA-class II in a minority 
of patients. 
 
Expression of the Wilms' 
tumor suppression gene 
together with monocyte 
differentiation in the M1 AML 
cell line. 
Megakaryocyte Thrombopoietin + IL-3 or 
SCF 
Increased expression of 
platelet-specific antigens 
in the M-O7e AML cell line 
Erythroid differentiation Erythropoietin Further erythroid diff. for  
patients with erythroleuk.  
 
Table 2b: Candidate drugs for differentiation induction (Tallman, 1996) 
 
 
Cytotoxic drugs 
cytarabine, daunorubicin, 6-thioguanine
combinations of cytosine arabinoside
thioguanine plus retinoic acid plus 
hexamethylene or dimethylformamide 
Altered Histone Acetylation histone deacetylase inhibitors 
butyrates 
monosaccharide butyrate derivatives 
High-Dose Methylprednisolone  
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Metal Chelators dithizone  
ATRA and Vitamin D3 Analogs  
 
Recently, it has been shown that the ligation of the CD44 surface antigen 
by specific anti-CD44 monoclonal antibodies or with its natural ligand, 
hyaluronan, can induce myeloid differentiation in AML1/2 to AML5 
subtypes (Charrad et al., 1999). We and others could also show 
differentiation induction upon CD44 ligation with anti-CD44 antibody, A3D8 
in AML cell lines HL60, U937, THp-1, KG1-a and NB4 (Charrad et al., 
2002; Peer Zada et al., 2003). This shows a new development for targeted 
differentiation therapy in AML. 
 
1.3 Adhesion Receptor CD44  
CD44 is a ubiquitous multistructural and multifunctional cell surface 
adhesion molecule involved in cell-cell and cell-matrix interactions, cell 
traffic, lymph node homing, presentation of chemokines and growth factors 
to cells and transmission of growth signals mediating hematopoiesis and 
apoptosis (Denning et al., 1989; Ghaffari et al., 1997; Naor et al., 2002; 
Shimizu et al., 1989; Taher et al., 1996; Underhill, 1992). It is a widely 
distributed glycoprotein encoded by a single copy gene, located on the 
short arm of chromosome 11 in human (Goodfellow et al., 1982) and on 
chromosome 2 in mice (Colombatti et al., 1982), spanning approximately 
50 kb of human DNA (Screaton et al., 1992) and contains 20 exons 
(Ghaffari et al., 1999; Screaton et al., 1992). Differential splicing and post-
translational modifications (-N- and O- glycosylations and 
glycosaminoglycanation) result in the generation of isoforms containing 
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variably sized extra and intra cellular domains (85-230 kda) (Brown et al., 
1991; Dougherty et al., 1991; He et al., 1992; Figure 3). The smallest 
CD44 molecule (85-95 kda), which lacks the entire variable region, is 
standard CD44 (CD44s). As it is expressed mainly on cells of 
lymphohematopoietic origin including those with functional properties of 
primitive progenitors, CD44s is also known as hematopoietic CD44 
(CD44H) (Harn et al., 1991; Naor et al., 2002).  
Hyaluronic acid (HA), an important component of the extracellular 
matrix (ECM), is the principal ligand of CD44 (Miyake et al., 1990a). Other 
CD44 ligands include the ECM components collagen, fibronectin, laminin 
and chondroitin sulfate, in addition to ECM-unrelated serglycin, addressin, 
osteopontin ligands (Naor et al., 2002; Underhill, 1992). Interaction 
between HA and CD44 delivers important signals to normal and 
transformed CD44-bearing cells (Lesley et al., 1993). As a target of 
mediating differentiation, CD44 deserves considerable attention in view of 
its role in transmitting signals that can modulate cell proliferation, survival 
and differentiation as well as their prevalence among leukemic cells 
(Liesveld et al., 1994; Moll et al., 1998; Reuss-Borst et al., 1992; Verfaillie, 
1998). A compelling body of evidence suggests outside-in signaling 
through CD44 (Lowell and Berton, 1999; Shattil et al., 1998) when ligated 
with its natural ligand, hyaluronic acid (Aruffo et al., 1990; Miyake et al., 
1990a) or with specific monoclonal antibodies (MoAbs). Much interest was 
focused on CD44 when it was reported that an antibody directed against a 
particular variant of CD44 blocked metastasis of a rat carcinoma (Legras 
et al., 1998). Subsequent publications suggested that CD44 may have 
early diagnostic and prognostic value (Bendall et al., 2000a; Ghaffari et al., 
1995; Legras et al., 1998). 
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Figure 3. CD44 structure: transmembrane and cytoplasmic domains. ERM 
denotes ezrin, radixin, moesin (adapted from Naor D 2002).  
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1.3.1 CD44: Role in hematopoiesis 
It has been shown that CD44 is involved in the regulation of hematopoiesis 
(Khaldoyanidi et al., 1999). This was demonstrated in studies involving 
administration of anti-CD44 monoclonal antibodies to a mouse Dexter type 
long-term bone marrow culture (LTBMC), which prevented the formation of 
neutrophil granulocytes and macrophages (Miyake et al., 1990b; Naor et 
al., 2002). The production of B-lineage lymphocytes in White lock and 
White LTBMC was also blocked by anti-CD44 MoAb (Naor et al., 2002). 
Similar results were obtained from different species (Khaldoyanidi et al., 
1997; Miyake et al., 1990b; Moll et al., 1998). Other in vitro models of 
hematopoiesis have shown that the signals delivered by HA and 
transduced by the CD44 receptor of the precursor cells are involved in the 
augmented proliferation and differentiation of the cells (Miyake et al., 
1991). CD44 antibodies capable of stimulating hematopoiesis in LTBMC 
have also been described (Khaldoyanidi et al., 2002; Rossbach et al., 
1996). Taken together, these data indicate that CD44 is important for the 
interaction of hematopoietic cells with the bone marrow microenvironment 
and is involved in the regulation of hematopoietic cell production and 
differentiation (Moll et al., 1998; Rossbach et al., 1996; Sandmaier et al., 
1990). 
1.3.2 CD44 in AML: Role as therapeutic target  
In animal models, it was shown that CD44 specific antibodies inhibit local 
tumor growth and metastatic spread (Naor et al., 2002) indicating that 
CD44 may confer a growth advantage on some neoplastic cells and, 
therefore, could be used as a target for cancer therapy. When considering 
therapeutic targeting, the diversity of the CD44 molecule, because of its 
variable region, has an advantage over other proinflammatory molecules 
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(for example; L-selectins, integrins, mucosal addresin cell adhesion 
molecule-1, vascular cell adhesion molecule-1, TNF-alpha, IFN-y and IL-
6), which have a much more restricted structure. Hence, the molecular 
flexibility of the CD44 receptor provides us with an excellent opportunity to 
target pathological CD44, while leaving normal CD44 undamaged. The 
importance of CD44 in AML came to focus when it was reported that CD44 
delivers a differentiation signal to leukemic blast cells that may be 
exploited to create new therapies for AML (Charrad et al., 1999). CD44 
was previously known to be expressed by blast cells from most AML 
patients and is elevated in expression in patients with AML as well as 
chronic myeloid leukemia (Ghaffari et al., 1996; Kortlepel et al., 1993). 
Other studies have shown expression of CD44 variant exons in AML to 
correlate with poor prognosis (Bendall et al., 2000a; Ghaffari et al., 1995; 
Legras et al., 1998). 
 
1.4 Transcription factor c-Jun 
 Recent studies have revealed a number of mechanisms by which 
transcription factors regulate differentiation and these mechanisms provide 
a useful framework to discuss how hematopoietic differentiation proceeds 
in a largely irreversible fashion. These mechanisms include autoregulation, 
inhibition of alternative pathway, activation of lineage specific genes, 
inhibition of proliferation and induction of apoptosis. 
 Among various transcription factors, we focused our attention on c-
Jun, an AP-1 transcription factor which was one of the first mammalian 
transcription factors to be identified (Angel and Karin, 1992) and found to 
regulate a wide range of cellular processes including cell proliferation, 
death, survival, differentiation and cell cycle progression (Bakiri et al., 
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2000; Behre et al., 1999a; Kovary and Bravo, 1991a; Schreiber et al., 
1999a; Shaulian and Karin, 2001; Smith and Prochownik, 1992; Wisdom 
et al., 1999). This property stems primarily from its structural and 
regulatory complexity. AP-1 is not a single protein, but a menagerie of 
dimeric basic region leucine zipper (bZip) proteins that belong to the Jun 
(c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1 & Fra-2), Maf (c-Maf, MafB, 
MafA, MafG / F/ K & Nrl) and ATF (ATF2, LRF1 /ATF3, B-ATF, JDP1, 
JDP2) sub families which recognize either TPA responsive elements (5 
TGAG/ CTCA 3) or camp responsive elements (CRE, 5 TGACGTCA 3) 
(Ryseck and Bravo, 1991). c-Jun is the most potent transcriptional 
activator in its group (Hirai et al., 1989). Comparison of c-Jun sequences 
among species reveals high degree of homology. Mouse c-Jun protein 
shares 96, 81 and 72 % identity with its human, chicken and Xenopus 
counterparts respectively (Mechta-Grigoriou et al., 2001). c-Jun can form 
homo or heterodimers with other members of the Jun or Fos family (Hirai 
and Yaniv, 1989). The relative binding affinities of distinct dimer 
combinations depend on the specific DNA sequence and on the promoter 
context (Halazonetis et al., 1988; Kerppola and Curran, 1991).  
1.4.1 c-Jun: Role in proliferation and cell cycle progression 
The role of c-Jun in promoting normal cell growth was first 
demonstrated by the use of neutralizing antibodies or anti-sense RNA 
which block entry into S phase (Kovary and Bravo, 1991b; Riabowol et al., 
1992). Moreover, overexpression of c-Jun alters cell cycle parameters and 
increases the proportion of cells in S, G2 and M relative to G1 phases of 
the cell cycle (Pfarr et al., 1994). The role of c-Jun in promoting cell growth 
has been further highlighted from studies of c-Jun deficient mouse 
embryonic fibroblasts (Hilberg et al., 1993; Johnson et al., 1993). 
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Fibroblasts lacking c-Jun exhibit a severe proliferation defect. Cyclin D1 is 
only poorly activated in these cells leading to a cell cycle block (Wisdom et 
al., 1999). Other studies have demonstrated accumulation of p53 and its 
target, p21 in c-Jun deficient fibroblast (Schreiber et al., 1999a). On the 
role of c-Jun in the mammalian UV response, it was shown that c-Jun is 
necessary for UV-irradiated cells to escape from p53-dependent growth 
arrest and to re-enter the cell cycle (Shaulian et al., 2000). These 
observations link directly c-Jun dependent signaling to the cell cycle 
machinery (Figure 4). Alternatively, the cell cycle dependent variations in 
Jun protein levels would constitute a novel reciprocal link between the cell 
cycle machinery and a transcription factor (Bakiri et al., 2000; Peer Zada et 
al; 2003). 
G0 G1 S
p16Ink4a JunB
Cdk2/Cdk4/6
Cyclin D1
c-Jun
Ras
JunD p19Arf
Mdm2p53
p21
CD44
anti-CD44
 
Figure 4. Cell cycle gene regulation by Jun proteins (colour legends 
indicate the results of this study) 
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1.4.2 Cell cycle    
It is a universal process by which cells divide and participate to the 
growth and development of organism. G1 phase is precisely regulated to 
coordinate normal cell division with cell growth, whereas replication of 
DNA during S phase is precisely ordered to prevent inadequate events that 
will lead to genomic instability and cancer. The cell cycle machinery as 
such, is a highly coordinated process in which cyclins, cyclin dependent 
kinases (CDKs) and their inhibitors (CDKIs) are differentially regulated 
(Gitig and Koff, 2000; Koepp et al., 1999; Matsushime et al., 1994; Muller 
et al., 1993; Sherr, 1994). Each cyclin can associate with one or more of 
the Cdk family and successive ways of cyclin/CDKs complexes drive cells 
through the cell cycle, acting in G1 to initiate S phase and in G2 to initiate 
mitosis. While levels of CDKs remain constant through the cell cycle, 
expression of cyclins varies following periodic transcriptional or post-
transcriptional regulations so that each cyclin has a unique pattern of 
expression during the cell cycle. Since cyclin abundance is rate limiting, 
the different CDKs get activated upon binding to their specific cyclin 
partner provided that these subunits are available. During the G1 phase of 
the cell cycle, two classes of cyclins get successively activated: D type 
cyclins (cyclins D1, D2 and D3) (Steinman, 2002) and cyclin E (cyclins E1 
and E2) (Koepp et al., 1999). These cyclins associate with their respective 
partners, CDK4 or CDK6 for cyclin D and CDK2 for cyclin E to induce their 
kinase activities (Bates et al., 1994a; Meyerson and Harlow, 1994). 
Activated CDK4/CDK6 and CDK2 are required for phosphorylation of the 
retinoblastoma protein (pRb), an event that leads to the release of Rb-E2F 
repressor complex and hence, induction of E2F-dependent genes and cell 
cycle progression (Bates et al., 1994b). Cyclins D and CDK4/6 are 
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responsible for the first phosphorylation of pRb, while cyclin E/CDK2 
operates on both the second pRb phosphorylation and the control of S-
phase entry. The activity of G1 cyclin-Cdk complexes is regulated, at least 
in part, by CDKIs, among which two members, p21 and p27 play specific 
roles. Evidence is accumulating that CDKIs are targets of extracellular and 
intracellular signals that regulate cell growth and differentiation (Harper et 
al., 1993a; Nead et al., 1998; Nishitani et al., 1999; Steinman et al., 
1994a). The p21 inhibitor is known to be triggered by antiproliferative and 
differentiation signals and as a mediator of p53 induced cell cycle arrest 
after DNA damage (Steinman et al., 1998). 
 
1.4.3 Regulation of c-Jun 
The regulation of AP-1 activity in general and c-Jun in particular, is 
complex. Regulation can occur through: i) changes in gene transcription 
and mRNA turnover; ii) effects on protein turnover; iii) post-translational 
modifications that modulate its transactivation potential and iv) interactions 
with other transcription factors that can either synergize or interfere with 
AP-1 activity (Behre et al., 1999a; Rangatia et al., 2002). In addition to 
being a transcriptional activator, some biological effects of c-Jun are 
mediated by gene repression (Passegue and Wagner, 2000; Shaulian et 
al., 2000; Schreiber et al., 1999b).  
1.4.3.1 Transcriptional regulation  
The c-jun gene is expressed in many different cell types at low levels 
and its expression is enhanced in response to many stimuli inclunding TPA 
(in a protein-kinase C-dependent manner), growth factors (EGF, NGF, 
FGF), UV irradiation or cytokines (Hill and Treisman, 1995; Karin and 
Hunter, 1995). The c-jun promoter region is highly conserved between 
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mouse, rat and the human transcription initiation site share a 94% identity 
(Pfarr et al., 1994). The c-jun promoter (Figure 5) contains potential 
binding sites for several transcription factors, including SP1 (Rozek and 
Pfeifer, 1993), NF-Jun (nuclear factor jun) (Brach et al., 1992), CTF 
(CCAAT transcription factor) and AP-1 itself (Angel et al., 1988a). 
Induction of c-jun expression by extracellular stimuli is mediated through a 
TRE-like site (jun1) located in the proximal region of the murine c-jun 
regulatory sequences, which is preferentially recognized by a c-Jun/ATF2 
heterodimer (van Dam et al., 1998). In the distal part of the c-jun promoter, 
a second AP-1 like site (jun2) also mediates the c-jun responsiveness to 
TPA or insulin and growth factor stimulation (Hagmeyer et al., 1993; Stein 
et al., 1992). As ATF2 alone cannot confer TPA-inducibility of c-jun, the c-
jun gene is thus upregulated by its own product (Angel et al., 1988b). 
 
Figure 5: c-jun promoter and binding sites for transcription factors 
 
1.4.3.2 Posttranslational regulation  
Despite its inducible expression, most cell types contain a certain 
basal level of c-Jun protein prior to stimulation and the TRE site in its 
promoter is constitutively occupied (Angel et al., 1987; Rozek and Pfeifer, 
1993). Following exposure to stimuli, the N-terminal Jun Kinases (JNK) 
members of the MAPK family, are activated leading to rapid 
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phosphorylation of preexisting c-Jun and ATF2 proteins (Devary et al., 
1992; Gupta et al., 1995). Phosphorylation of c-Jun on residues Ser63 and 
Ser73, located within its transactivation domain, potentiates its 
transactivation properties by recruiting the coactvator protein, CBP, a 
histone acetylase (Arias et al., 1994), thereby enhancing c-jun 
transcription. This type of JNK mediated regulatory control involves two 
distinct steps; endogenous basal c-Jun protein is first activated by 
posttranslational modifications and the phosphorylated form of c-Jun 
induces subsequently its own transcription by a positive auto-regulatory 
loop. The JNKs are the only kinases that activate c-Jun; Erk1 and Erk2 
MAPKs are inefficient in phosphorylating the N-terminal part of c-Jun 
although they have been shown to phosphorylate a cluster of inhibitory 
residues located next to the basic domain (Mechta-Grigoriou et al., 2001).  
1.4.3.3 Regulation at the level of protein-protein interactions  
           Recent data (Peer Zada et al., 2003; Rangatia et al., 2002) 
suggests that c-Jun expression might be a key event in the decision of a 
myeloid cell to proliferate or to differentiate. These effects are mediated 
through protein-protein interactions. For example, c-Jun has been shown 
to interact with PU.1 and act as a JNK independent coactivator of PU.1 to 
induce monocytic differentiation (Behre et al., 1999a). c-Jun is reported to 
interact with C/EBPalpha, an important transcription factor involved in 
granulocytic differentiation. Downregulation of c-Jun by C/EBPalpha is an 
event that leads to granulocytic lineage commitment (Rangatia et al., 
2002). 
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1.5 Aim of the Study  
The aim of this study is to elucidate the molecular mechanisms 
involved in differentiation induction and proliferation arrest upon CD44 
ligation in human myeloid cell line models and thereby, help providing new 
insights into anti-proliferative and differentiation therapy of AML.  
In particular we sought to demonstrate the role of c-Jun in influencing 
cell proliferation and cell cycle progression in myeloid cells, since only 
scarce data are available in this field. Moreover, it would be of interest to 
investigate the role of c-Jun and cell cycle regulatory molecules in parallel 
to further strengthening our knowledge on this ubiquitous transcription 
factor. 
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2. Materials 
 
2.1 Mammalian cell lines 
 
HL60                  (human myeloid cell line, myeloblastic) 
U937                  (human myeloid cell line, monoblastic) 
                   
2.2 Plasmids 
pc-jun (-1780/+731) 
pc-jun (-952/+731) 
pc-jun (-716/+731) 
pc-jun (-345/+731) 
pc-jun (-180/+731) 
pc-jun (-63/+731) 
pc-jun (delpAP-1)-c-jun promoter with proximal AP-1 site deleted 
pc-jun (deldAP-1)-c-jun promoter with distal AP-1 site deleted 
pc-jun (delpdAP-1)-c-jun promoter with both AP-1 sites deleted 
pGL3 
pMV7-cjun 
pMV7 
 
2.11 Antibodies 
. Monoclonal anti-CD44 antibody, A3D8 (Sigma)  
Isotype matched antibody (IgG1, Sigma) or J173 (Immunotech) 
Fluorescein isothiocynate (FITC) MoAbs to CD11b (FITC, 
immunotech, IgG1) and CD71 (FITC, DAKO, IgG1) 
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c-Jun (anti-rabbit, sc-45, Santa Cruz),  
c-Fos (anti-rabbit polyclonal, sc-52, Santa Cruz), 
JunB (anti-mouse monoclonal IgG1, sc-8051, Santa Cruz),  
CDK2 (anti-rabbit, sc-163),  
CDK4 (anti-rabbit, sc-260),  
cyclin D1 (ant-rabbit, sc-718), 
p21 (anti-mouse, sc-817) and  
pRb (anti-mouse monoclonal, sc-102 Santa Cruz).  
JNK1 (anti-rabbit, sc-474),  
ERK1 (anti-rabbit, sc-94 Santa Cruz), 
phospho-c-Jun (anti-mouse monoclonal, sc-822 Santa Cruz) and 
β -tubulin (anti-rabbit, sc-9104). 
 
3. Methods 
3.1 Proliferation assays: 
To assess the proliferation state of cells after various treatments, 
MTT proliferation assay kit (Boehringer Mannheim, Germany) and 
BrdU incorporation (FLUOS kit) were used according to 
manufacturers instructions with minor modifications. 
 
3.1.1 MTT assay:  
     It is a non-radioactive, colorimetric assay system used for the 
quantitative determination of cellular proliferation and activation. The 
assay is based on the reduction of the yellow tetrazolium salt MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromid) to 
purple formazan crystal by metabolic active cells involving NADH 
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and NADPH. The resulting solution can then be quantified by 
multiwell spectrophotometer.  
Cells were incubated with or without A3D8 for 1-4 days in 96 
well plates. 10µL MTT labeling reagent (5mg/ml) was added every 
day to each well and the plates were incubated at 37°C for 4 hours. 
The resulting formazon crystals were solubilized by adding 100µL of 
solubilization buffer (10% SDS in 0.01M HCl) per well and the plates 
were incubated at 37°C overnight. The absorbance of the formazon 
measured at 575 nm was used to account for the proliferation state 
of cells.  
3.1.2 BrdU incorporation: 
5-bromo-2´-deoxuridine (BrdU), a thymidine analogue, which 
gets incorporated into cellular DNA during the S phase of the cell cycle 
and thus, a direct measure of cell proliferation, was also used. The assay 
was performed by using in situ cell proliferation kit, FLUOS (Roche, 
Mannheim Germany, cat.no. 1810740). The BrdU assay involves: (i) 
labeling of the cells with BrdU, (ii) fixing and denaturating BrdU labeled 
cells by acid, (iii) detecting incorporated BrdU with a fluorescein-
conjugated anti-BrdU monoclonal antibody and (iv) analyzing the samples 
on a flow cytometer. 
3.2 Cell cycle analysis and Flow Cytometry 
To investigate the surface expression of myeloid differentiation and 
proliferation markers, FACS analysis was performed. HL60 and U937 cells 
(3X105 cells/ml) were stimulated for 36 hours with A3D8 (20µg/ml) and 
then stained with FITC or PE labeled antibodies at a concentration of 
10µg/ml at 4°C for 30 minutes and washed twice with FACS buffer (PBS, 
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3% FCS, 0.01% NaN3). Fluorescence was then analyzed on Coulter 
EPICS XL / XL- MCL SystemII Software. Data were collected after 5000 
cell analysis (per sample) and the results shown as scatter diagrams or 
expressed as D- value which is calculated as: 
Mean fluorescence intensity (MFI) ratio = Mean of sample stained 
with MoAb / Mean of isotype 
control MoAb 
Then the percentage of difference between MFI ratio of sample incubated 
with or without A3D8 was calculated, giving a D-value (Pisani et al., 1997) 
for each sample. The D-value for unstimulated control was arbitrarily 
chosen and that of stimulated sample expressed relative to it. Negative D-
values indicate more MFI of stimulated sample than unstimulated and 
hence, implies increased expression of the particular marker. Similarly, 
positive D values imply decreased expression of the marker. For the cell 
cycle analysis, cells with or without A3D8 treatment were centrifuged at 
1500 rpm for 3 min, washed with PBS and then the DNA was stained with 
100µg/ml propidium iodide for 30 min at 4°C protected from light. The cells 
were then analyzed with the FACScan (Beckton-Dickinson) for different 
cell populations. 
3.3 RNA isolation and semi-quantitative RT-PCR 
  Total RNA was isolated from 7X105 cells before and after treatment 
with A3D8 (20µg/ml) and IgG1 (20µg/ml) using RNeasy Mini kit (Qiagen). 
100 ng of RNA was used for first strand cDNA synthesis in a 20µL reaction 
with 10X RT buffer, dNTP (5mM), RNasin (1U/µL), oligo dT (1µM) and the 
reaction was incubated at 37°C for 90 minutes. Equal amounts of cDNA 
were taken for c-jun PCR amplification using a Qiagen kit. Aldolase was 
used as an internal control. The PCR cycling program consisted of 30 
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cycles of 94°C for 2 minutes, 55°C for 1 minute and 72°C for 80 seconds 
using DNA thermal cycler (Perkin Elmer). PCR products of ~971bp (c-jun) 
and ~580bp (Aldolase) were separated by 1.2% agarose gel 
electrophoresis and visualized by ethidium bromide staining with UV 
irradiation. The primers used for PCR amplification were for c-jun (Gene 
Bank ACC. No. J04111): forward primer 5`-ACT GCA AAG ATG GAA 
ACG AC- 3`(bp 1264-1283) and reverse primer 5`-AAA ATG TTT GCA 
ACT GCT GC- 3`(bp 2235-2254); and for aldolase: forward primer 5`-AGC 
TGT CTG ACA TCG CTC ACC G- 3` and reverse primer 5`-CAC ATA 
CTG GCA GCG CTT CAA G- 3`. 
3.4 Quantitative Real-time PCR in AML patient samples 
Quantitative Real-time PCR using the Light CyclerTM Systems (LC) 
offers real time monitoring of PCR product formation. During the run the 
PCR product increases logarithmically which can be identified and the 
starting concentration of the target DNA determined. We used the Fast 
Start DNA SYBR Green I-Kit (Roche Diagnostics, Mannheim, Germany) as 
a mastermix. SYBR Green I Dye is a fluorescence dye, which binds to 
double-stranded DNA. The fluorescence signal was recorded at the end of 
each elongation phase and the increasing amounts of PCR product can be 
monitored from cycle to cycle. We quantified the expression of c-jun in 
AML patient samples as well as of the housekeeping gene G6PD to 
control for variances in the cDNA synthesis step. Thus, we performed 
relative measurement of the target gene expression by comparison to 
G6PD. G6PD plasmid: pGdBBX, kindly provided by A. Hochhaus, 
University of Mannheim was serially diluted to 10000fg, 1000fg and 100fg 
and used as a standard curve for the calculation of c-jun and G6PD 
concentrations.  
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 PCR was performed using 2µl master mix (LC Fast Start DNA 
Master SYBR Green 1 Cat. No: 3003230, Roche), 2µl of respective cDNA, 
4mM MgCl2, 7.5µM of each primer and water to a final volume of 20µl. 
Amplification occurred in a three step cycle procedure initiated by a 10 
minute denaturation at 95°C to activate the polymerase: 95°C, 0s, 
annealing 64°C, 10s, and extension 72°C, 25s for 35 cycles. Fluorescence 
of SYBR Green I was measured after each extension step at 530 nm in 
channel F1. The final PCR cycle is followed by a melting curve analysis to 
confirm PCR product identity and differentiate it from non-specific, e.g. 
primer-dimer products. For that, the products are denatured at 95°C, 
annealed at 65°C, and then slowly heated up to 95°C with fluorescence 
measurement at 0.2°C increments. Some amplified products were 
analysed by electrophoresis on 1% ethidium bromide stained agarose 
gels. The estimated size of the amplified fragments matched the 
calculated size: for c-jun (409 bp) and G6PD (343 bp). 
3.5 Immunoblot analysis 
Total cellular protein was extracted from HL60 and U937 cells before 
and after A3D8 treatment and subjected to electrophoresis on 10% SDS-
PAGE gels. The western blotting procedure was performed and the blots 
detected with the ECL system as described previously (Behre et al., 
1999b). Anti-β-tubulin antibody (Boehringer Mannheim) was used as 
internal loading control on the same blot after stripping. Immunoblot 
analysis was performed for c-Jun (anti-rabbit, sc-45, Santa Cruz), c-Fos 
(anti-rabbit polyclonal, sc-52, Santa Cruz), JunB (anti-mouse monoclonal 
IgG1, sc-8051, Santa Cruz), CDK2 (anti-rabbit, sc-163), CDK4 (anti-rabbit, 
sc-260), cyclin D1 (ant-rabbit, sc-718), p21 (anti-mouse, sc-817) and pRb 
(anti-mouse monoclonal, sc-102 Santa Cruz). The other antibodies used 
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for the Immunoblot analysis were JNK1 (anti-rabbit, sc-474), ERK1 (anti-
rabbit, sc-94 Santa Cruz), phospho-c-Jun (anti-mouse monoclonal, sc-822 
Santa Cruz) and ß -tubulin (anti-rabbit, sc-9104).  
3.6 Immunocomplex kinase assay 
After described treatments, HL60 cells were washed with cold PBS 
and RIPA lysates prepared at different time points. Lysates were collected 
by centrifugation for 30 min and protein concentrations were quantified by 
the Bradford assay (Bio-Rad Laboratories, Germany). 200 µg of protein 
was incubated with 2 µg of anti-CDK2 or anti-CDK4 antibody at 4° C for 2 
h with rotation. Protein A agarose beads (20 µl) was then added and the 
incubation continued for another 2 h. Immunocomplex beads were washed 
twice with PBS buffer and three times with kinase buffer (150 mM NaCl; 1 
mM EDTA; 50 mM Tris-HCl, pH 7.5; 10 mM MgCl2; and 10 mM DTT). 
Kinase activity was assayed by incubating the beads at 37° C for 30 min 
with 25 µl kinase buffer, 3 µg histone H1 (Upstate, Germany; CDK2) or Rb-
fusion protein (Santa Cruz; CDK4), 10 µM ATP, and 4 µCi [γ-32P] ATP 
(3000 Ci/mmol). Samples were then boiled for 5 min in 2X sample buffer, 
electrophoresed through a 12% SDS-polyacrylamide gel, dried, and 
phosphorylated histone H1 and Rb proteins were visualized by auto 
radiography and quantified by Aida 2.1 software program. 
3.7 Transient transfections using Effectene 
Effectene transfection reagent is a unique non-liposomal lipid 
formulation designed to achieve high transfection efficiencies. Effectene 
allows transfections in the absence of serum, which was important to rule 
out any serum-induced fluctuations in c-jun promoter activity used in this 
study. In the first step of Effectene-DNA complex formation, the DNA (in 
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this case c-jun promoter/luciferase constructs) was condensed by 
interaction with the Enhancer in a defined buffer system. Effectene reagent 
was then added to the condensed DNA to produce Effectene-DNA 
complexes, which are mixed with the medium and directly added to the 
cells. In this way, the cells were transiently transfected with 1µg c-jun 
promoter/luciferase constructs and pRL-0 plasmid per well of the six well 
plates. 18 hours after transfection, A3D8 was added to the wells to a final 
concentration of 20µg/ml for additional 6 hours. Promoter activities were 
determined by measuring the luciferase activity with the Dual Luciferase 
Assay System (Promega). Firefly Luciferase activities of different c-jun 
promoter constructs in pGL3 were normalized to the Renilla Luciferase 
values of pRL-0 (Behre et al., 1999c). 
3.8 Stable cell lines overexpressing c-Jun 
To generate cell lines overexpressing c-Jun, the retrovirus-derived 
cDNA expression vector was used for the study. This vector, designated 
pMV7-cjun was kindly provided by Dr. Yaniv. The vectors are described 
elsewhere (Kirschmeier et al., 1988). pMV7-cjun and the empty vector 
pMV7 (lacking the c-Jun cDNA insert) were transfected into HL60 cells by 
electroporation (300V/975µF). After 48 hours, the cells were transferred 
into selective medium containing 1 µg/ml G418. After 1 week in the 
selection medium, the cells transfected with pMV7 or pMV7-cjun were then 
stimulated with A3D8 or IgG with a final concentration of 20 µg/ml. 36 
hours after treatment with A3D8, the cells were analyzed for CD11b and 
CD71 expression. The expression of c-Jun in c-Jun overexpressing HL60 
cells was measured by Real-time PCR and western blot analysis. 
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4. Results 
4.1 CD44 ligation inhibits the proliferation and induces terminal 
differentiation of myeloid leukemia cells 
A reverse in blockage of differentiation of acute myeloid leukemia 
cells upon CD44 ligation led us to analyze the molecular mechanism of 
CD44 mediated effects. To achieving this, we used human myeloid cell 
lines HL60 (myeloblastic) and U937 (monoblastic) as our model systems in 
addition to anti-CD44 monoclonal antibody A3D8 to activate CD44 
signaling. To validate our system we first performed proliferation and 
differentiation studies. Treatment of HL60 and U937 cells with the anti-
CD44 MoAb antibody A3D8 for different time points resulted in a dramatic 
decrease of proliferation (Figure 6). We used the non-radioactive 
quantification of cell proliferation and cell viability (MTT assay) for 
investigating the proliferation state of HL60 (Figure 6A) and U937 cells 
(Figure 6C). The decreased proliferation of these myeloid cells also 
correlated with decreased CD71 (transferrin receptor) expression (Figure 
6B and 6D). CD71 is known to be a proliferation marker and transferrin 
receptor expression is related to the proliferative state of the cells as well 
as the induction of differentiation (Theil, 1990); thus, the number of CD71 
molecules is larger in cells with a high proliferation rate and vice versa. 
CD71 downregulation has been extensively characterized in cells treated 
with DMSO, ATRA and TPA (Horiguchi-Yamada and Yamada, 1993; 
Horiguchi-Yamada et al., 1994). Upon CD44 ligation by A3D8 in HL60 and 
U937 cells, we observed a drastic decrease in CD71 expression (47% and 
7%, respectively) compared to the controls. It is important to note that 
CD71 expression was higher in HL60 cells (>90%, Figure 6B, upper left 
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panel) as compared to U937 cells (<20%, Figure 6D, upper left panel). No 
inhibitory effect was observed with the isotype matched MoAb control.  
To rule out the possibility of a cytotoxic effect of A3D8 we performed 
differentiation studies. Treatment of human myeloid HL60 and U937 cells 
with A3D8 induced striking changes in the morphology of these cells 
characteristic of terminal differentiation (Figure 7A and 7C). For example, 
A3D8 treated cells showed decreased nucleus: cytoplasm ratios, 
segmented nuclei, few nucleoli and chromatin condensation. The effects 
like the formation of aggregates in culture and adherence became visible 
only after 12-18 hours of A3D8 treatment. We also analyzed the 
expression of the cell differentiation marker CD11b in HL60 and U937 cells 
(Figure 7B and 7D) and observed that its expression was increased in both 
cell lines after CD44 ligation. The expression of CD11b increased to ~31% 
after A3D8 treatment compared to unstimulated (~7%) and isotype control 
(~9.6%) in HL60 cells (Figure 7B, upper left panels). Corresponding to this, 
the D-value (calculated as described in the Materials and Methods) was 
found to be 57 after A3D8 treatment in HL60 cells compared to +30 for 
the control (Table 3). In U937 cells, the expression of CD11b increased to 
~22% after A3D8 treatment compared to unstimulated (~6%) and isotype 
control (~7%) (Figure 7D, upper left panels). Corresponding to this, the D-
value was found to be 78 after A3D8 treatment in U937 cells compared to 
+30 for the control (Table 3).   
 
   
 
 35
C
D
 7
1
(B)
Unstimulated Isotype A3D8
77.4 % 47.4 %97.8 %
(A) HL60
Days of Incubation
Ab
so
rb
an
ce
(5
75
 n
m
)
0
0,5
1
1,5
2
2,5
3
1 2 3 4
Unstim.
Isotype
A3D8
C
D
 7
1
(D)
7.14 %14.3 % 10.4 %
Unstimulated Isotype A3D8
(C) U937
Days of Incubation
A
bs
or
ba
nc
e
(5
75
 n
m
)
0
0,5
1
1,5
2
2,5
3
1 2 3 4
Unstim.
Isotype
A3D8
 
Figure 6. Decreased proliferation in myeloid leukemia cells upon        
CD44 ligation. 
A, C; MTT assay: Cells were cultured in 96-well plates with or without A3D8 and 
isotype control antibody (20 µg/ml) for 1-4 days and then MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromid) incorporation was measured. The absorbance 
at 575 nm (OD575), which is an estimate of the proliferation state of cells, was 
measured using an Elisa plate reader. Results are shown as mean ± SD of three 
independent experiments, each experiment in triplicate. B, D; FACS analysis: Cells 
were cultured 1X105/200 µL/well for 36 hours in the presence or absence of A3D8 (20 
µg/ml). They were then analyzed for their surface CD71 (transferrin receptor) 
expression and the results were presented as scatter diagrams. The percentage 
values (upper left panel) in each scatter diagram represents the % positive cells of 
the marker (i.e. cells on upper left quadrant). 
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Figure 7 (A & B). Differentiation induction in myeloid leukemia cells 
upon CD44 ligation. 
Morphological analysis of HL60 cells: A, Cytospin preparations of cells stained with 
May-Grünwald-Giemsa after in vitro treatment for 36 hours with medium alone, with 
isotype antibody (20 µg/ml), and A3D8 (20 µg/ml). B, Changes in the differentiation 
marker (CD11b) presented as scatter diagrams before and after CD44 ligation with 
A3D8, respectively.  
 
 
 
 
 
 
 
   
 
 37
U937
Unstimulated Isotype A3D8
5.97 % 7.05 % 22.5 %
C
D
11
b
(C)
(D)
 
 
Figure 7 (C & D). Morphological analysis of U937 cells: C, Cytospin preparations 
of cells stained with May-Grünwald-Giemsa after in vitro treatment for 36 hours with 
medium alone, with isotype antibody (20 µg/ml), and A3D8 (20 µg/ml). D, Changes in 
the differentiation marker (CD11b) presented as scatter diagrams before and after 
CD44 ligation with A3D8, respectively.  
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Table 3: 
HL 60 
           Mean fluorescence 
           Intensity (MFI) ratio  
          D-value 
             (%) 
Marker 
Unstim. Isotype A3D8 Unstim. Isotype   A3D8 
CD11b 1.11 1.03 1.41 30.00 + 23.00 - 57.00 
CD71  4.47 3.10 1.35 30.00 +25.00 +12.00 
 
 
 
U937 
 
           Mean fluorescence 
           Intensity (MFI) ratio  
          D-value 
             (%) 
Marker 
Unstim. Isotype A3D8 Unstim. Isotype   A3D8 
CD11b 1.07 1.02    1.32 30.00 + 20.00 - 78.00 
CD71  1.00 1.03 0.98 30.00 -  36.00 +24.00 
 
 
Table: This table represents the MFI ratios and the corresponding D-Values 
(calculated as in Materials & Methods Section) for CD11b and CD71 expressions as 
analyzed by Flow Cytometry. (+) Indicates decreased expression and (-) Indicates 
increased expression. 
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4.2 CD44 ligation with A3D8 induces a G0/G1 arrest in myeloid 
leukemia cell lines 
Cell cycle arrest is a common feature of cells undergoing terminal 
differentiation and defective proliferation. Based on the growth inhibitory 
and differentiation inducing effects of A3D8 on myeloid leukemia cell lines, 
we investigated their cell cycle progression in response to A3D8. The DNA 
content analysis showed that the myeloid cells underwent a G0/G1 arrest 
(Figure 8). Interestingly, we observed a change in cell cycle distribution at 
6 hours of A3D8 treatment in HL60 cells as compared to untreated cells or 
cells treated with the isotype antibody. The proportion of cells in G0/G1 
phase increased from 54% (controls) to 67% in A3D8 treated cells after 24 
hours (Figure 8A). This was mirrored by a decrease in the proportion of 
cells in the S and G2 phase from 13% (controls) to 2% in A3D8 treated 
cells and from 23% (controls) to 4% in A3D8 treated cells, respectively. 
The effect of A3D8 on cell cycle was dose dependent in the range from 5-
20 µg/ml. It is important to mention the increase in the proportion of dead 
cells to 14-27% after 24-36 hours of A3D8 treatment, which could be 
attributed to the induction of terminal differentiation. These data suggest 
that the growth inhibitory effect of A3D8 on myeloid cells is in part, due to 
its effect on cell cycle progression. 
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Figure 8. CD44 ligation arrests myeloid leukemia cells in the G1       
phase of cell cycle. 
A, The figure represents cell cycle distribution (propidium iodide staining) of 
HL60 cells before and after A3D8 treatment.  
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4.3 CD44 ligation with A3D8 induces the expression of p21 and 
downregulates the expression of major G1 regulatory proteins 
Based on the effects of A3D8 on G1 phase accumulation we 
hypothesized the role of major G1 regulatory proteins. We examined the 
effect of A3D8 on p21, pRb, cyclin D1, cyclin D2, CDK2 and CDK4 protein 
expression. Our results show that A3D8 treatment of HL60 cells caused 
marked upregulation of p21 protein expression after 6 hours (Figure 9A, 
lane 3). The increased p21 protein level persisted for 12 hours and was 
undetectable thereafter. The p21 level was undetectable in untreated or 
isotype treated cells (Figure 9A, lanes 1 and 2). Since HL60 cells are p53 
negative due to homozygous deletions (Steinman et al., 1998), it is 
conceivable that p21 induction by A3D8 is p53 independent. Our results 
also show that treatment of HL60 cells with A3D8 for 12 and 24 hours 
markedly decreases the expression of pRb (Figure 9D). It is important to 
note the presence of a slow migrating band (upper band) and a faster 
migrating band (lower band) when the blot was probed with anti-Rb 
antibody. The upper band corresponds to the hyperphosphorylated (*) form 
while the lower band corresponds to the hypophosphorylated form 
(Savatier et al., 1994; Slack et al., 1993). Inhibition of pRb correlated with 
decreased levels of CDK2 and CDK4 (Figure 9B and 9C). There was no 
effect on CDK6 expression (Figure 9D).  
4.4 CD44 ligation with A3D8 inhibits CDK2 and CDK4 activities 
CDK2 and CDK4 kinase activities have been shown to operate in the 
G1 phase. G0/G1 arrest by A3D8 led us to analyze the kinase activities 
associated with these CDKs. Antibodies against CDK4 and CDK2 were 
used to perform immunocomplex kinase assays using recombinant Rb 
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fusion protein and purified histone H1 protein as substrates, respectively. 
Consistent with its effect on cell cycle progression, A3D8 treatment 
inhibited CDK4 and CDK2 kinase activities (Figure 9G and 9H). The 
densitometry analysis showed that A3D8 treatment after 24 hours caused 
greater than 4-fold inhibition of CDK4 kinase activity. Interestingly, CDK2 
kinase activity showed similar results. To normalize for the 
immunoprecipitation (IP) efficiency, a western blot for the respective Cdks 
was also performed after IP. IgG served as IP control. The results (Figure 
9G and 9H) clearly show the specificity of our kinase reaction and that 
CDK2 and CDK4 were not degraded during the kinase reaction. It is 
important to note that it might seem surprising to correlate CDK activity 
with Rb phosphorylation after A3D8 treatment (Figure 9E) in which Rb IF8 
(anti-mouse, sc-102) was used. However, this is not the case. Western 
blot of the lysates when probed with phospho-specific Rb antibody (pRb 
Ser-780, sc-12901, Santa Cruz) gave the expected results. Our results 
show that treatment of the cells with A3D8 led to decreased Rb 
phosphorylation (Figure 9F) thereby correlating with decreased CDK 
activity. The difference in the two results could thus, be attributed to 
antibody specificities as well as to different readouts. These data suggest 
that induction of G0/G1 arrest by A3D8 in myeloid cells involves p21 
induction and/or inhibition of CDK activity. 
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Figure 9 (A, B, C & D). CD44 ligation induces the expression of p21 and 
downregulates the expression of major cell cycle regulatory proteins. 
The figure shows Immunoblot analysis from whole cell lysates of HL60 cells (p53 
negative), for A, p21, a cyclin dependent kinase inhibitor probed with anti p21 antibody 
(SC); B, Cdk2; C, Cdk4; D, Cdk6. Lanes: 1, 2, unstimulated and isotype control, 3-5, 
A3D8 stimulated (6, 12, 24 hours, respectively). The numbers underneath the blot 
indicate protein/ respective β-tubulin ratios after densitometric analysis (Aida 2.1 
software program).  
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Figure 9 (E, F, G & H). Immunoblot analysis from whole cell lysates of HL60 cells 
for E, pRb; F, phospho-Rb; G and H, in vitro kinase assay for CDK2 and CDK4 
respectively: HL60 cells were treated with 20 µg/ml A3D8 or isotype antibody for 
different time points. Whole cell lysates were then prepared and immunoprecipitated 
with CDK2 (G) and CDK4 (H) antibodies as described under Methods section. Histone 
H1 was used as substrate for CDK2 and Rb-fusion protein as substrate for CDK4 in the 
in vitro kinase assay. Also shown (in the right panel) is a western blot of CDK2 and 
CDK4 after IP of the respective kinases. 
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4.5 CD44 ligation downregulates c-jun mRNA and c-Jun protein 
expression 
The AP-1 transcription factor c-Jun functions as a proliferation-
promoting gene and is involved in cell cycle progression. Consequently, 
the expression of c-Jun would be expected to change in response to 
decreased proliferation and cell cycle arrest of HL60 and U937 cells upon 
CD44 ligation with A3D8. Our results show that there is a drastic decrease 
in c-jun mRNA expression (Figure 10A and 10B) upon A3D8 treatment of 
the myeloid cells. c-jun expression was also downregulated in AML patient 
blasts after 6 and 12 hours of A3D8 treatment in vitro (Figure 10C). We 
also observed a dramatic decrease in c-Jun protein expression upon CD44 
ligation (Figure 10A and 10B). To rule out a general toxic effect, we show 
that the expression of c-Fos (Figure 10C) is not altered in a similar fashion. 
These data suggest that the downregulation of c-Jun contributes to A3D8 
mediated growth arrest in myeloid cells.  
4.6 CD44 ligation downregulates human c-jun promoter activity via 
AP-1 sites 
To elucidate the molecular mechanisms underlying the 
downregulation of c-Jun expression by CD44 ligation, we performed 
promoter studies. U937 and HL60 cells were transiently transfected with 
different c-jun promoter/luciferase constructs and then subjected to A3D8 
treatment. The promoter constructs used in this study (Materials, 2.2) were 
kindly provided by Vedeckis (Wei, 1998). Our results show that the full-
length c-jun promoter (bp-1780/+731) activity was downregulated 12 fold 
after A3D8 treatment (Figure 11). It was not a vector effect since A3D8 had 
no effect on pGL3, in which c-jun promoter constructs were subcloned. 
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Figure 10 (A, B & C). CD44 ligation downregulates c-jun mRNA 
expression in myeloid leukemia cells and AML patient samples. 
Negative gel image showing c-jun mRNA transcript amplified with specific c-jun 
primers. A, HL60 cells; B, U937 cells; C, In AML patient samples the expression of c-
jun was measured by quantitative Real-time PCR. The bars represent the mean ratio 
of c-jun to G6PD of 4 AML patient samples.  
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Figure 10 (D, E & F). CD44 ligation downregulates c-jun protein 
expression in myeloid leukemia cells. D, Immunoblot analysis for c-Jun 
expression from whole cell lysates of HL60 cells and E, data from U937 cells; F, 
Immunoblot analysis for c-Fos from whole cell lysates of HL60 cells. The numbers 
underneath the blot indicate the c-Jun/ß-tubulin ratios after densitometric analysis 
(Aida 2.1 software program). 
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As a positive control for our promoter studies, we also show that TPA 
increases the c-jun promoter activity (data not shown). To map site(s) in 
the c-jun promoter responsible for the downregulation, a series of c-jun 
promoter deletion mutant-luciferase gene chimeric plasmids with variable 
ends (from bp -1780 to bp -63) (Wei et al., 1998) were also transiently 
transfected into the cells. The results show that the downregulation of c-jun 
promoter activity is lost after deletion of the region between bp -1780 to 
63 (with -63/+731 construct), where two AP-1 sites (bp -64 and bp -182) 
are located (Figure 11A and 11C). Various reports implicate AP-1 
modulation in the regulation of proliferation and differentiation. Among 
important regulatory elements previously identified in the c-jun promoter 
are two AP-1 sites, a proximal one (pAP-1) located between bp -71 and bp 
and a distal one (dAP-1) located between bp-190 and bp-183. Both AP-1 
sites are involved in transcriptional regulation in response to UV irradiation 
and phorbol esters. These data and our results led us to further map the 
AP-1 site responsible for the downregulation. Upon deletion of the proximal 
(delpAP-1) or the distal (deldAP-1) AP-1 sites in the c-jun promoter, we 
observed a similar downregulating effect, while the effect was lost upon 
deletion of both AP-1 sites (Figure 11B). The loss of repression effect 
cannot be a simple activation because the promoter activity in the 
presence of A3D8 is the same as that of the promoter alone (Figure 11B, 
last two bars), although in the presence of A3D8 antibody the activity of the 
promoter with two mutant AP-1 sites has a higher activity than either of the 
singly mutated constructs (Figure 11B, compare bars with A3D8 
treatment). These results show that both AP-1 sites are important for the 
downregulation of c-jun promoter activity upon CD44 ligation with A3D8. 
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Figure 11 (A). CD44 ligation downregulates c-jun promoter activity via 
AP-1 sites. 
The figure represents a series of c-jun promoter deletion mutants-luciferase gene 
chimeric plasmids with variable ends (from bp -1780 to bp -63).37 Each construct was 
transiently transfected into HL60 and U937 cells. Transfected cells were then treated 
with A3D8, six hours before measurement of luciferase activity. Promoter activity is 
normalized for transfection efficiency by dividing firefly luciferase activity by renilla 
luciferase activity of a co-transfected reporter plasmid pRL-0. Results are presented 
as mean± SD of at least three independent experiments. pc-jun represents the 
promoter constructs and pGL3 is the vector in which the promoter constructs were 
subcloned.  
A, Deletion analysis of c-jun promoter. 
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Figure 11 (B & C). Both AP-1 sites are required for c-jun promoter 
downregulation upon CD44 ligation. 
B, Mutagenesis analysis of the AP-1 sites in the c-jun promoter. 
C, A model of c-jun promoter showing AP-1 sites. 
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4.7 A3D8 treatment decreases c-Jun phosphorylation and JNK 
expression 
The decreased transactivation property of c-Jun by A3D8 could be 
mediated through a change in the phosphorylation status of c-Jun. To 
investigate if A3D8 treatment of the cells caused decreased c-Jun 
phosphorylation we performed Immunoblot analyses of cell lysates from 
HL60 cells using a phospho-specific (Ser63) anti-c-Jun antibody (Figure 
12). No phosphorylated c-Jun was detected at 12 or 24 hours after A3D8 
treatment (Figure 12, lanes 4 and 5), although c-Jun phosphorylation was 
detected at 6 hours and in the controls (Figure 12, lanes 1-3). Furthermore, 
our results showed that A3D8 treatment drastically decreased the 
expression of JNK1, ahead of decreased c-Jun phosphorylation (Figure 
12B). The effect seems to be JNK specific since only an insignificant effect 
on ERK1 expression could be detected (Figure 12C). These data suggest 
that inhibition of c-Jun expression by A3D8 result from inhibition of c-Jun 
phosphorylation via the JNK pathway. Taken together, our data indicate 
that inhibition of c-Jun/ AP-1 activity may be the mechanism by which 
A3D8 inhibits the proliferation and causes cell cycle arrest in myeloid cells.  
4.8 Overexpression of c-Jun in HL60 cells overcomes the 
proliferation-inhibiting effects of A3D8 
To further characterize the role of c-Jun biologically, we 
overexpressed c-Jun in HL60 cells to investigate if the effects of 
proliferation-inhibition and differentiation-induction by A3D8 can be 
overcome. HL60 cells were transfected with the pMV7-cjun retroviral 
construct as described in the Materials and Methods section.  
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Figure 12. CD44 ligation decreases c-Jun phosphorylation and JNK 
expression. 
The figure represents Immunoblot analysis of whole cell extract of HL60 cells probed 
with anti-phospho c-Jun (Ser 63), anti-JNK1 and anti-ERK1 antibodies (Santa Cruz 
Biotechnologies). A, phospho c-Jun, B, JNK1, and C, ERK1. Lanes: 1, 2, 
unstimulated and isotype control, 3-5, A3D8 stimulated (6, 12, 24 hours, respectively). 
The numbers underneath the blot indicate the protein/respective ß-tubulin ratios after 
densitometric analysis (Aida 2.1 software program). 
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After selection of the cells in G418, they were kept in G418 free media with 
and without A3D8. We observed that the expression of CD71 was 
markedly increased in pMV7-cjun transfected cells as compared to vector 
alone (Figure 13A). Moreover, c-Jun overexpressing HL60 cells showed 
increased cell numbers (trypan blue cell counting) as compared to cells 
containing vector alone over a period of 3 days (Figure 13B). We could 
clearly observe a slow growth in vector (pMV7) transfected cells under 
constant selection pressure whereas pMV7-cjun transfected cells showed 
a higher growth rate under similar conditions. As a more direct measure of 
cell proliferation, we also performed a bromodeoxyuridine (BrdU) 
incorporation assay. Our results clearly show that pMV7-cjun transfected 
cells incorporate more BrdU than pMV7 transfected cells and hence, the 
former have more proliferation potential than the later (Figure 8C). After 24 
hours post transfection, the percentage of pMV7-cjun transfected cells 
showed >50% BrdU incorporation as compared to <10% in the control. It is 
important to mention here that c-Jun overexpression in HL60 cells did not 
lead to any cell death as determined by propidium iodide staining (data not 
shown). Thus, c-Jun expression and cell proliferation in fact, do correlate in 
myeloid leukemia HL60 cells. The expression of c-Jun was 25 fold higher 
in pMV7-cjun transfected cells as compared to the controls (Figure 13D 
and 13E). Furthermore, we observed that A3D8 treatment of untransfected 
HL60 cells and the cells transfected with vector alone (pMV7) caused 
decreased proliferation and hence, decreased CD71 expression as 
compared to the isotype control (Figure 6 and 13E, panel i, ii). On the 
contrary, in HL60 cells overexpressing c-Jun (pMV7-cjun), A3D8 treatment 
did not lead to any changes in CD71 expression as compared to the 
isotype control (Figure 13E, panel iii). A similar pattern was observed with 
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CD11b expression (Figure 13F), although the differentiation-inducing ability 
of c-Jun in c-Jun overexpressing HL60 cells is not of the same extent as 
the proliferation-inducing ability. These results clearly indicate that 
downregulation of the proliferation promoting transcription factor c-Jun is a 
prerequisite for A3D8 mediated proliferation-inhibition in our settings.  
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Figure 13 (A, B & C). Ectopic overexpression of c-Jun in HL60 cells 
increases their proliferation and prevents A3D8 mediated inhibition of 
proliferation. 
A, The figure represents an overlay of different peaks (WinMDI 2.8 software program) 
from FACS analysis for CD71 expression of HL60 cells after electroporation with 
pMV7-cjun and pMV7 and selection in G418. In addition to empty vector control, 
untransfected HL60 cells also served as control. B, Trypan blue cell counting of cells 
transfected with pMV7 and pMV7-cjun when the cells were under selection pressure. 
C, pMV7 and pMV7-cjun transfected cells were also analyzed for BrdU-incorporation 
as a direct measure of proliferation. 
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Figure 13 (D, E, F & G). D, This figure represents Real time PCR for c-jun 
expression in c-Jun overexpressing HL60 cells. The bars represent c-jun/G6PD ratio of 
untransfected HL60 cells, transfected with empty vector, pMV7 and with pMV7-cjun. E, 
This represents western blot analysis for c-Jun expression in c-Jun overexpressing 
HL60 cells. Lanes: 1, in vitro-translated c-Jun, 2, reticulocyte lysate, 3, untransfected 
HL60 cells, 4, pMV7 transfected cells and 5, pMV7-cjun transfected cells. F, G, 
Overexpression of c-Jun in HL60 cells prevents A3D8 mediated growth inhibition 
and differentiation induction. The figure represents overlay from FACS analysis for 
CD71 and CD11b expression in c-Jun overexpressing HL60 cells before and after 
treatment with A3D8. After selection in G418 for 1 week, HL60 cells were stimulated 
with A3D8 at final concentration of 20 µg/ml for further 36 hours and the cells were 
analyzed for CD71 and CD11b expression by flow cytometry.  
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5. Discussion 
Hematopoiesis is a complex cellular evolutionary process in which 
pluripotent stem cells are committed to progenitor cells that proliferate and 
differentiate to generate the full complement of mature blood cells. A 
defect in this evolutionary tree characterizes acute myeloid leukemia 
(AML). As a result of a differentiation block in AML, there is an 
accumulation of immature cells (termed blasts), which remain in the 
proliferative pool and a suppression of normal hematopoiesis (Tenen et al., 
1997; Lowenberg et al., 1999). The stage at which the block occurs 
defines a particular AML subtype (AML1/2 to AML6). In experimental 
systems and in specific clinical settings the differentiation block can be 
overcome and leukemic cells can terminally differentiate after exposure to 
either chemical agents (Kantarjian, 1999) or by use of monoclonal 
antibodies (both conjugated and unconjugated). Any such agent (or 
treatment), which induces the differentiation of cancer cells, thus 
preventing further proliferation, is known as differentiation cancer 
therapy. In the case of AML, the single successful example of 
differentiation therapy is the use of all trans-retinoic acid (ATRA), which is 
used in the treatment of promyelocytic AML3 subtype (APL) (Waxman, 
2000). However, APL makes only 5-15 % of all leukemias and ATRA is 
ineffective in other subtypes of AML. The question arises: Is it possible to 
apply differentiation induction therapy to other subtypes of AML as well? 
The answer came from Charrad et al (Charrad et al., 1999) when they 
reported that it is possible to reverse the differentiation block in AML blasts 
from all AML subtypes by targeting an adhesion receptor CD44 with anti-
CD44 antibodies. This stimulated the clinical potential for CD44-targeted 
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differentiation therapy. However, owing to a number of complications 
CD44-targeted therapy has not yet been tested in patients. Moreover, with 
the fact that AML cells are responsive to factors that preferentially 
stimulate hematopoietic cells, one could argue in favour of more direct 
treatment strategies aimed downstream of CD44 ligation. Alternatively, 
understanding the mechanism of the CD44-mediated differentiation block 
reversal in AML could lead to novel therapeutic strategies. The present 
study was undertaken to address this aspect: to investigate the effect of 
CD44 ligation by the anti-CD44 monoclonal antibody A3D8 on the 
proliferation of myeloid leukemia cells and the underlying molecular 
mechanisms.  
Our results demonstrate that ligation of CD44 with A3D8 causes 
growth arrest and induces terminal differentiation of human myeloid 
leukemia cell lines HL60 and U937 through the downregulation of c-Jun 
expression via AP-1 sites (Figure 10 and 11). Furthermore, decreased JNK 
expression and a consequent decrease in c-Jun phosphorylation may be 
involved in A3D8 mediated downregulation of the c-Jun promoter activity 
(Figure 12). The downregulation of c-Jun expression is a prerequisite for 
the growth inhibitory effects of A3D8 since overexpression of c-Jun is able 
to prevent A3D8 mediated effects (Figure 13). We also show an induction 
of G0/G1 arrest by A3D8 (Figure 8), which is accompanied by induction of 
p21 and inhibition of pRb, CDK2 and CDK4 protein expression (Figure 9). 
Although our results show c-Jun as mediator of A3D8 mediated growth 
arrest, we do not rule out other mechanisms by which A3D8 can block 
proliferation of myeloid leukemia cells. 
Our results revealed that CD44 ligation with A3D8 decreases the 
proliferation and leads to the induction of terminal differentiation of HL60 
   
 
 59
and U937 cells (Figure 6 and 7). A3D8 and HA were previously shown to 
induce differentiation in AML blast and myeloid cell lines (Charrad et al., 
2002; Charrad et al., 1999). However, we did not use HA in our study 
because of its low affinity for CD44 expressed on myeloid cells (Allouche 
et al., 2000). The induction of differentiation after three days of A3D8 
treatment clearly shows that the anti-proliferative effect of A3D8 was not a 
toxic effect, but that differentiation commitment can be a stochastic 
process involving loss of proliferative potential (Liebermann and Hoffman, 
2002). In conjunction, CD44 ligation with A3D8 alone is sufficient to induce 
terminal differentiation in myeloid cell lines without the requirement of 
cofactors or the cytokine microenvironment niche as reported previously 
(Lemischka, 1997). It is also likely that differentiation induction via CD44 is 
epitope specific, since J173 (Immunotech), another monoclonal antibody 
against CD44, is unable to induce differentiation in myeloid cell lines and 
arrest cells in G1 phase. A3D8 and J173 have already been reported to 
bind different epitopes (Allouche et al., 2000). 
The growth inhibitory effect of A3D8 on myeloid cells is due to an 
arrest of these cells in G0/G1 phase, due to induction of p21 expression 
and /or inhibition of CDK2/CDK4 expression. These findings could be 
explained considering that an exit from the cell cycle is a prerequisite for 
growth arrest and cell differentiation. The treatment-induced cell cycle 
arrest was shown to be important for invitro and invivo AML cell sensitivity 
to other therapeutic agents. Cell cycle arrest with other potent inhibitors of 
proliferation and inducers of differentiation of human myeloid leukemia cell 
lines have also been reported, for example, TGFß1, RA, TPA and vitamin 
D analogs. p21 when overexpressed has been shown to mediate growth 
arrest, contribute to restriction point G1 arrest and is upregulated in 
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myeloid differentiation models (Steinman et al., 1994a; Steinman et al., 
2001; Steinman et al., 1994b; Steinman et al., 1998). A major target of p21 
inhibition is the cyclin-cdk2 kinase complex whose activity is required for 
G0/G1 progression into S-phase. P21 can interact with cyclin-cdk 
complexes and is capable of inhibiting kinase activity associated with 
these complexes (Harper et al., 1993b). A3D8 led to inhibition of CDK 
kinase activities. Thus, increase of p21 and/or the decrease of CDK2 and 
CDK4 expression in HL60 upon A3D8 treatment may be sufficient to inhibit 
kinase activity required for G0/G1 progression into S phase. Our results, 
taken together with other findings, suggest that induction of p21 and /or 
inhibition of CDK expression may play a causative role in CD44 mediated 
growth arrest. Interestingly, p21 induction seems to be a common 
mechanism of differentiation inducers of human myeloid leukemia cells 
(e.g; ATRA, AS2O3 etc), irrespective of whether the induction of p21 is p53 
dependent or independent (Jiang et al., 1994; Steinman et al., 1994a). For 
example, p21 induction by A3D8 is p53 independent since HL60 cells are 
p53 negative due to homozygous deletions. Furthermore, reduced kinase 
activities of CDK2 and CDK4 were accompanied with the 
underphosphorylation of retinoblastoma protein (Rb), which is known to 
sequester the transcription factor, E2F, thereby preventing cells from 
further entering the cell cycle progression. These results suggest a role of 
CDK/Rb pathway in cell cycle arrest by CD44 signaling (Figure 9F).  
Previous analyses have suggested an important role of activator-
protein-1 (AP-1) transcription factor, c-Jun in regulating proliferation, 
differentiation and cell cycle progression (Shaulian and Karin, 2001; 
Schreiber et al., 1999b; Mechta-Grigoriou et al., 2001). c-Jun acts as a 
convergence point of many signaling pathways and its activity is regulated 
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in a cell type-dependent manner by a variety of signals that are relayed 
through transcriptional and post-transcriptional mechanisms. In spite of 
wealth of knowledge regarding the regulatory mechanisms impinging on c-
Jun, not all the biological functions of the protein are accounted for 
satisfactorily in myeloid cells. For example, most of the studies concerning 
c-Jun and cell cycle have been performed in fibroblast cells (Kovary and 
Bravo, 1991a). We present here the first evidence linking c-Jun to 
proliferation and cell cycle in human myeloid cells via CD44 signaling. Our 
results demonstrate that the expression of c-Jun is downregulated upon 
CD44 ligation with A3D8, both at mRNA and protein level (Figure 10). The 
downregulation of c-jun upon A3D8 treatment was also observed in AML 
patient blasts (Figure 10C). However, the effect of CD44 ligation on c-jun 
expression in AML patients is less prominent than in myeloid cell lines. 
This could be because of the difference in cytogenetic set up in different 
AML patients. Moreover, the requirement of c-Jun could differ in normal 
versus transformed cells, in tumor cells of different cell lineages, or in cells 
having undergone transformation via different mechanisms. To rule out the 
downregulating effects on c-Jun as a consequence of A3D8 toxicity, we 
also show that A3D8 treatment does not downregulate the expression of c-
Fos and CDK6 non-specifically. 
 The downregulation of c-Jun by A3D8 could be the result of the 
inhibition of AP-1 transcriptional activity and/or block of JNK activity 
indirectly, given that JNK is proposed to bind tightly to c-Jun and release it 
only after phosphorylation. To explore these possibilities, transient 
transfections of c-jun promoter/ luciferase constructs in myeloid cells 
revealed that the downregulation effect of A3D8 on c-Jun expression might 
be a direct result of decreased c-jun promoter activity. The results revealed 
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that both AP-1 sites are responsible for the downregulation of c-jun 
promoter activity by CD44 signaling (Figure 11). Transcriptional activation 
of the c-Jun protein is dependent on phosphorylation at Ser 63 and Ser 73, 
located in its transactivation domain (TAD) (Smeal et al., 1991), a process 
mediated by c-Jun N-terminal Kinase (JNK). Phosphorylation of c-Jun is 
known to potentiate its transactivation properties (Binetruy et al., 1991; 
Hagmeyer et al., 1993). Conversely, downmodulation of transcriptional 
activity of c-Jun would mean decreased JNK and reduced c-Jun 
phosphorylation. Our results also show that the expression of JNK is 
decreased upon A3D8 treatment, with a consequent decrease in the level 
of c-Jun phosphorylation (Figure 12A and 12B). We used JNK1 since it 
has been shown to preferentially bind c-Jun and phosphorylate c-Jun 
(Minden et al., 1994; Kallunki et al., 1994). The role of other JNKs remains 
to be determined. The effect of A3D8 is JNK specific because ERK 
expression is not changed under similar conditions (Figure 12C). It is 
important to note here that c-Fos expression did not change upon A3D8 
treatment (Figure 9C). Fos is known to be regulated by the ERK pathway 
(Chou et al., 1992; Deng and Karin, 1994). The decreased JNK expression 
and hence, c-Jun phosphorylation could in turn, be because of the positive 
effect of A3D8 treatment on p21 protein level (Figure 4A). It has been 
reported that interaction of p21 with JNK inhibits JNK activity (Shim et al., 
1996; Patel et al., 1998). Thus, it is conceivable that the inhibition of JNK 
by p21 may be the mechanism for the downregulation of c-Jun 
phosphorylation and hence, the transactivation potential of c-jun. 
To prove the biological significance of downregulation of c-Jun 
expression by CD44 ligation in the context of myeloid cell growth arrest, we 
performed overexpression studies in HL60 cells. A3D8 mediated 
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proliferation-inhibition in HL60 cells was prevented by c-Jun 
overexpression (Figure 13E) suggesting that c-Jun/ AP-1 activity is one of 
the molecular targets downstream of CD44 signaling. BrdU incorporation, 
CD71 expression (Theil, 1990; Hochhaus et al., 2000) and Trypan blue cell 
counting which were used as a measure of cell proliferation clearly 
demonstrate that c-Jun in fact, increases the proliferation of myeloid cells. 
c-Jun overexpression had little effect on CD11b expression (Figure 13F). 
In the context of the role of c-Jun in myeloid cell differentiation, this might 
seem surprising. However, the role of c-Jun in differentiation could be time 
limiting. It is important to mention here that the downregulation of c-Jun 
expression upon CD44 ligation is in accordance with our recent findings in 
which the transcription factor C/EBPα was shown to downregulate c-Jun 
expression to induce myeloid differentiation (Rangatia et al., 2002).  
In summary, it is thus, conceivable to propose a model (Figure 14) 
which shows that the downregulation of c-Jun expression along a pathway 
which involves inhibition of JNK by p21 resulting in decreased c-Jun 
phosphorylation and hence decreased promoter activity concomitant with 
decreased cell cycle proteins may be an important mechanism for 
regulating CD44 mediated differentiation-induction and proliferation-arrest 
with A3D8. Our results provide a framework for further investigations and 
suggest that clarification of the mechanisms of regulation may reveal novel 
targets for anti-proliferative and /or differentiation therapy in AML. 
Elucidation of the basic pathways underlying myeloid differentiation and 
understanding how these pathways are disrupted in AML will help define 
future therapeutic approaches to AML. 
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Figure 14. Model of how CD44 ligation inhibits proliferation and 
blocks cell cycle of myeloid leukemia cells by downregulating c-Jun 
expression. 
The figure shows a possible mechanism for the growth inhibitory effect of anti-CD44 
antibody A3D8 in myeloid cells. The growth arrest involves decreased c-Jun 
expression along a pathway, which involves inhibition of JNK by p21 resulting in 
decreased c-Jun phosphorylation and hence decreased promoter activity concomitant 
with decreased cell cycle proteins. 
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6. Summary 
 
We present here the first evidence linking CD44 signaling to c-Jun 
expression and cell cycle progression in myeloid cell line models. CD44 
ligation with the anti-CD44 monoclonal antibodies have been shown to 
induce differentiation and inhibit the proliferation of human acute myeloid 
leukemia (AML) cells, and c-Jun is involved in the regulation of these 
processes. The effects of anti-CD44 monoclonal antibody A3D8, on 
myeloid cells were associated with specific disruption of cell cycle events 
and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied 
by an increase in the expression of p21, attenuation of pRb 
phosphorylation and associated with decreased CDK2 and CDK4 kinase 
activities. We observed that A3D8 treatment of AML patient blasts and 
HL60/U937 cells led to the downregulation of c-Jun expression at mRNA 
and protein level. Transient transfection studies showed the inhibition of c-
jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, 
A3D8 treatment caused a decrease in JNK protein expression and a 
decrease in the level of phosphorylated c-Jun. Ectopic overexpression of 
c-Jun in HL60 cells was able to induce proliferation and prevent the anti-
proliferative effects of A3D8. Targeting of G1 regulatory proteins and the 
resulting induction of G1 arrest by A3D8 may provide new insights into 
anti-proliferative and differentiation therapy of AML.  
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7. Zusammenfassung 
 
 Wir zeigen in dieser Arbeit zum ersten Mal, daß in myeloischen 
Zellmodellen die CD44-Signaltransduktion mit c-Jun und dem Zellzyklus 
verbunden ist. Es ist bekannt, daß die Bindung eines Antikörpers gegen 
CD44 an den CD44-Rezeptor in Zellen von akuten myeloischen Leukämien 
(AML) Differenzierung induziert und Proliferation inhibiert, sowie daß c-Jun 
in die Regulierung dieser Prozesse involviert ist. Die Effekte des Anti-CD44-
Antikörpers A3D8 auf myeloische Zellen waren mit einer spezifischen 
Störung von Ereignissen des Zellzyklus und der Induktion eines G0/G1-
Arrestes assoziiert. Die Induktion dieses G0/G1-Arrestes wurde von einer 
Erhöhung der Expression von p21, der Abschwächung der Phosphorylierung 
von Rb und von verminderten Niveaus der Expression von CDK2 und CDK4 
begleitet. Wir beobachteten, daß die Behandlung von Blasten von Patienten 
mit AML und Zellen der Zellinien HL60 und U937 zu einer Verminderung von 
c-Jun auf dem mRNA- und Proteinlevel führte. Transiente Transfektionen 
zeigten die Inhibierung der Aktivität des c-Jun-Promoters durch A3D8, die 
beide AP1-Seiten einschloss. Desweiteren verursachte Behandlung mit 
A3D8 eine verminderte Expression des Proteins JNK und eine 
Verminderung des phosphorylierten c-Jun. Ektopische Überexpression von 
c-Jun in Zellen der Zellinie HL60 konnte Proliferation induzieren und die 
antiproliferativen Effekte von A3D8 verhindern. Der gezielte Eingriff in die 
Regulation der die G1-Phase des Zellzyklus regulierenden Proteine könnte 
neue Einsichten in die antiproliferative und Differenzierung induzierende 
Therapie der AML ermöglichen. 
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